Dashboard
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 4.17%
- Poor long term growth as Net Sales has grown by an annual rate of -5.90%
Flat results in Sep 26
With ROE of -7.5, it has a Very Expensive valuation with a 2.3 Price to Book Value
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Diversified Commercial Services
INR 17 Cr (Micro Cap)
NA (Loss Making)
20
0.00%
1.28
-7.51%
2.18
Total Returns (Price + Dividend) 
Latest dividend: 0.19999999999999998 per share ex-dividend date: Jul-29-2022
Risk Adjusted Returns v/s 
Returns Beta
News

Zenlabs Ethica Ltd Downgraded to Strong Sell Amid Weak Financials and Technical Setbacks
Zenlabs Ethica Ltd, a micro-cap player in the diversified commercial services sector, has seen its investment rating downgraded from Sell to Strong Sell as of 22 Oct 2026. This shift reflects deteriorating fundamentals, challenging valuation metrics, and a weakening technical outlook, signalling caution for investors amid persistent operational losses and underperformance against benchmarks.
Read More
Zenlabs Ethica Ltd Downgraded to Strong Sell Amid Weak Financials and Technical Deterioration
Zenlabs Ethica Ltd, a micro-cap player in the diversified commercial services sector, has been downgraded from a Sell to a Strong Sell rating as of 5 October 2026. This revision reflects deteriorating fundamentals, challenging valuation metrics, and a shift in technical indicators, signalling heightened risk for investors amid persistent operational losses and underwhelming market performance.
Read More
Zenlabs Ethica Ltd Downgraded to Sell Amid Mixed Technicals and Weak Financials
Zenlabs Ethica Ltd, a micro-cap player in the diversified commercial services sector, has seen its investment rating upgraded from Strong Sell to Sell as of 21 September 2026. This change reflects a nuanced shift in the company’s technical outlook amid persistent fundamental challenges and valuation concerns.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Change in Management
19-Nov-2026 | Source : BSEThe Board of Directors of the company at its meeting held today i.e. Thursday 19th November2026 have considered and approved the appointment of Mr. Ashok Kumar Gupta as Additional Director in the category of Non-Executive Independent Director of the company with effect from November 19th2026. The term of appointment as an Independent Director will be for a period of 5 (Five) years and the appointment is subject to the approval of shareholders of the company
Board Meeting Outcome for BOARD MEETING OUTCOME UNDER REGULATION 30 OF THE SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS)REGULATIONS2015
19-Nov-2026 | Source : BSEThe Board of Directors of the Company at their Meeting held today i.e. Thursday November 19 2026 have considered and approved the Appointment of Mr. Ashok Kumar Gupta (DIN: 07330108) as an Additional Director in the category of Non-Executive Independent Director of the Company for the period of 5 (Five) years with effect from November 19 2026.
Non-Applicability Of Regulation 23(9) Of SEBI (LODR) 2015
14-Nov-2026 | Source : BSEDeclaration regarding non-applicability of the Regulation 23(9) of the SEBI LODR2015 in respect of disclosure of related party transaction for the quarter ended 30th September2026.
Corporate Actions 
No Upcoming Board Meetings
Zenlabs Ethica Ltd has declared 2% dividend, ex-date: 29 Jul 22
No Splits history available
Zenlabs Ethica Ltd has announced 1:20 bonus issue, ex-date: 11 Oct 18
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 0 FIIs
Preet Remedies Limited (26.58%)
Hitesh Popatlal Oswal (6.79%)
38.6%
Quarterly Results Snapshot (Standalone) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is -19.61% vs 34.03% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is 84.21% vs 0.00% in Jun 2026
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is -7.00% vs -6.98% in Sep 2024
Growth in half year ended Sep 2025 is -22.22% vs -40.00% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is -5.44% vs -11.12% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -1,177.78% vs -30.77% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is -8.75% vs -12.19% in Mar 2025
YoY Growth in year ended Mar 2026 is -818.52% vs -35.71% in Mar 2025